PMID- 16249379
OWN - NLM
STAT- MEDLINE
DCOM- 20060404
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 107
IP  - 4
DP  - 2006 Feb 15
TI  - Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer.
PG  - 1505-12
AB  - Telomerase is considered a universal tumor-associated antigen (TAA) due to its 
      high rate of expression by cancers (approximately 90%), and clinical trials are 
      in progress to test the immunotherapeutical efficacy of antitelomerase 
      immunization in patients with cancer. However, the data concerning frequency and 
      functional activity of telomerase-specific cytotoxic T lymphocytes (CTLs) in 
      patients with cancer are few and conflicting, although their knowledge would be 
      mandatory to predict the efficacy of telomerase-specific immunotherapy in 
      selected patients. We performed this study to analyze frequency and cytolytic 
      function of circulating CD8+ T lymphocytes specific for the p540 telomerase 
      peptide in a series of human leukocyte antigen (HLA)-A2+ cancer patients. The 
      results show that most patients with cancer have circulating telomerase-specific 
      CD8+ T lymphocytes, but a high frequency of telomerase-specific CTLs are present 
      only in a fraction of them. Furthermore, CTL lines able to kill 
      telomerase-positive tumor cells, including autologous cancer cells, can be 
      expanded ex vivo from some, but not all, patients with cancer. In conclusion, the 
      results of the study support the development of clinical protocols using 
      telomerase peptides as an immunizing agent. However, they underline the necessity 
      to study single patients immunologically before undergoing vaccination, to select 
      the patients adequately, and to eventually adapt the immunization schedule to the 
      patient's immunologic status.
FAU - Filaci, Gilberto
AU  - Filaci G
AD  - Department of Internal Medicine and Center of Excellence for Biomedical Research 
      (CEBR), University of Genoa, Viale Benedetto XV no. 6, 16132 Genova, Italy. 
      gfilaci@unige.it
FAU - Fravega, Marco
AU  - Fravega M
FAU - Setti, Maurizio
AU  - Setti M
FAU - Traverso, Paolo
AU  - Traverso P
FAU - Millo, Enrico
AU  - Millo E
FAU - Fenoglio, Daniela
AU  - Fenoglio D
FAU - Negrini, Simone
AU  - Negrini S
FAU - Ferrera, Francesca
AU  - Ferrera F
FAU - Romagnoli, Andrea
AU  - Romagnoli A
FAU - Basso, Monica
AU  - Basso M
FAU - Contini, Paola
AU  - Contini P
FAU - Rizzi, Marta
AU  - Rizzi M
FAU - Ghio, Massimo
AU  - Ghio M
FAU - Benatti, Umberto
AU  - Benatti U
FAU - Damonte, Gianluca
AU  - Damonte G
FAU - Ravetti, Jean Louis
AU  - Ravetti JL
FAU - Carmignani, Giorgio
AU  - Carmignani G
FAU - Zanetti, Maurizio
AU  - Zanetti M
FAU - Indiveri, Francesco
AU  - Indiveri F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051025
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA-A2 Antigen)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - CD8-Positive T-Lymphocytes/*enzymology
MH  - Cell Line, Tumor
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Immunophenotyping
MH  - Lymphocyte Depletion
MH  - Male
MH  - Prostatic Neoplasms/*enzymology/*immunology
MH  - T-Lymphocytes, Cytotoxic/enzymology/immunology
MH  - Telomerase/*blood
EDAT- 2005/10/27 09:00
MHDA- 2006/04/06 09:00
CRDT- 2005/10/27 09:00
PHST- 2005/10/27 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2005/10/27 09:00 [entrez]
AID - S0006-4971(20)66404-7 [pii]
AID - 10.1182/blood-2005-01-0258 [doi]
PST - ppublish
SO  - Blood. 2006 Feb 15;107(4):1505-12. doi: 10.1182/blood-2005-01-0258. Epub 2005 Oct 
      25.